Indolent lymphomas: pushing the pace with novel agents

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Chemoimmunotherapy has been standard for indolent B-cell non-Hodgkin lymphomas (iNHL) for 20 years, achieving high response rates but often followed by relapse.
• Current treatment paradigms focus on maintaining efficacy while minimizing toxicity or achieving a cure for iNHL.
• Advances in understanding iNHL genetics and the tumor immune microenvironment are driving the development of novel therapies.

Observation:

• New therapeutic agents include immunomodulatory drugs (e.g., lenalidomide), B-cell receptor pathway inhibitors (e.g., ibrutinib, idelalisib), BCL-2 mimetics (e.g., venetoclax), and EZH2 inhibitors (e.g., tazemetostat).
• Immunotherapies aimed at enhancing the host immune response against malignant B cells are under investigation, including immune checkpoint inhibitors, agonist antibodies, antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor T cells.
• These novel therapies show promising early efficacy signals, suggesting potential for durable remissions.

Findings:

• The expansion of tolerable treatment options for iNHL is accelerating.
• New drug combinations hold promise for achieving definitive therapy in iNHL.
• Immunotherapies are being investigated for their potential to induce durable remissions, similar to allogeneic stem cell transplant.

Implications:

• Novel therapies may augment chemotherapy rather than replace it, aiming to improve patient quality of life and survival.
• A deeper understanding of iNHL biology is paving the way for more personalized and effective treatment strategies.
• The development of targeted agents and immunotherapies represents a significant shift in the management of indolent B-cell lymphomas.